J&J’s Rybrevant Results Provide Encouragement After Interim Analysis Sparked Jitters
The company announced topline results for MARIPOSA in EGFR-mutant NSCLC, showing positive progression-free survival and a favorable trend on overall survival.
You may also be interested in...
The upcoming European Society for Medical Oncology meeting in Madrid has a full slate of potentially practice-changing late-breaking clinical trials ready to be presented. Here, Scrip takes a look at five of the most eagerly anticipated.
The withdrawal of the targeted anticancer comes as no surprise after its Phase III missed in July, but it sets back Takeda’s expansion plans in the competitive therapy area.
Improvements in PFS compared to chemotherapy may help broaden Rybrevant’s indication in EGFR-mutated non-small cell lunger cancer. Investors await data from a head-to-head trial testing it versus AstraZeneca’s Tagrisso.